| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Kiniksa Pharmaceuticals (NASDAQ:KNSA) is set to give its latest quarterly earnings report on Tuesday, 2025-07-29. Here's what investors need to know before the announcement.
Analysts estimate that Kiniksa Pharmaceuticals will report an earnings per share (EPS) of $0.21.
Kiniksa Pharmaceuticals bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
During the last quarter, the company reported an EPS missed by $0.17, leading to a 4.21% increase in the share price on the subsequent day.
Here's a look at Kiniksa Pharmaceuticals's past performance and the resulting price change:
| Quarter | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| EPS Estimate | 0.28 | 0.13 | 0.03 | -0.07 |
| EPS Actual | 0.11 | -0.12 | -0.18 | -0.06 |
| Price Change % | 4.0% | -0.0% | -1.0% | -4.0% |
Shares of Kiniksa Pharmaceuticals were trading at $26.33 as of July 25. Over the last 52-week period, shares are up 2.32%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: KNSA
